Status:
TERMINATED
Effect of Topical CBD Cream for Degenerative Hallux Disorders
Lead Sponsor:
Rush University Medical Center
Collaborating Sponsors:
Mid-America Orthopaedic Association
Conditions:
Hallux Valgus
Hallux Rigidus
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Hallux rigidus and hallux valgus are chronic forefoot conditions associated with pain, inflammation and functional impairment. Topical cannabidiol (CBD) cream has been shown to decrease inflammation, ...
Detailed Description
Hallux rigidus and hallux valgus are chronic forefoot conditions associated with pain, inflammation and functional impairment. While operative interventions exist, nonoperative modalities are the main...
Eligibility Criteria
Inclusion
- Patients with a new diagnosis of hallux rigidus or hallux valgus
- VAS pain score of 4 or higher
- Age \> 18 years
- The patient provides informed consent
Exclusion
- A previous operative procedure to the first metatarsal for treatment of hallux valgus or hallux rigidus
- VAS pain score at presentation less than 4
- Concomitant hallux valgus and hallux rigidus on the ipsilateral side
- Allergy to CBD, Cannabidiolic acid (CBDa) or any other ingredient contained in the topical cream
- Pregnant patients
Key Trial Info
Start Date :
October 20 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2023
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04103814
Start Date
October 20 2019
End Date
May 15 2023
Last Update
October 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Midwest Orthopaedics at Rush
Chicago, Illinois, United States, 60612